Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Lymphoid 1CNS 1

Conditions

Melanoma 2Neoplasms 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Opdualag × Dermatologic × Clear all
NCT07281924 2026-05-29

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

University of Wisconsin, Madison

Phase 1/2 Recruiting
15 enrolled
Dermatologic

Melanoma

NCT05970497 2025-05-18

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Krystal Biotech, Inc.

Phase 1/2 Recruiting
240 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡